NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Edwards Lifesciences Corporation (EW) Stock Analysis

Edwards Lifesciences Corporation (EW) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

EW

$89.90

+$0.12 (+0.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EW with… →

EW Key Statistics

As of Sep 4, 2026
Trading
Open
$90.21
Previous Close
$89.78
Day's Range
88.40–90.21
52-Week Range
72.30–96.29
Volume
2.64M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$51.82B
P/E Ratio
53.51
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
26.62
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.94
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.96
EPS (ttm)Profit attributable to each share over the last twelve months.
1.68
Financials (FY)
Revenue (FY)
$6.07B+11.55%
Net Income (FY)
$1.07B−74.28%
Profit marginThe share of revenue left as profit after all costs and taxes.
15.43%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
576.40M
1-Year Return
+11.04%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
4.27M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+5.45%
2025+15.16%
2024−2.91%
2023+2.20%
2022−42.41%
2021+42.00%
2020+17.32%
2019+52.31%
2018+35.90%
2017+20.29%
2016 (partial year)−16.64%

As of September 4, 2026.

EW Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.07B$1.07B17.7%
2024$5.44B$4.17B76.7%
2023$5.01B$1.40B28.0%
2022$4.46B$1.52B34.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.07B$4.73B$1.64B$1.07B17.7%
2024$5.44B$4.32B$1.48B$4.17B76.7%
2023$5.01B$4.03B$1.49B$1.40B28.0%
2022$4.46B$3.74B$1.54B$1.52B34.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EW Valuation vs Medical Devices Median

Median of 151 stocks
MetricEWMedical Devices medianvs median
P/E53.5126.80100% above
P/S ratio7.962.98167% above
Profit margin15.43%−1.69%17.1 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Edwards Lifesciences Corporation (EW) is capitalised at $51.82B on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 16,000.

EW last closed at $89.90 on September 4, 2026. That is +$0.12 (+0.13%) against the previous close. Over the past 52 weeks the price has ranged from $72.30 to $96.29. The latest close sits 24.34% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.07B. That is +11.55% against the prior fiscal year, when revenue was $5.44B. Net income for the same year was $1.07B. That is −74.28% against the prior fiscal year. The reported profit margin is 15.43%. That is 17.1 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 1.68.

Across the 4 fiscal years on file, revenue moves from $4.46B in 2022 to $6.07B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 53.51. That is 99.66% above the Medical Devices median of 26.8. The forward P/E on file is 26.62. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.94. The price-to-sales ratio is 7.96. On price-to-sales that is 167.36% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +11.04%. Measured over 10 years, that is +8.82% a year compounded. The reported beta is 0.85. Daily returns over the trailing 10 years annualize to a volatility of 32.24%.

Growth & Income

The record shows no dividend for EW.

Across the complete calendar years on file, 2019 returned +52.31% and 2022 returned −42.41%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the price is +5.45%.

Peer Comparison

Edwards Lifesciences Corporation (EW) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Edwards Lifesciences Corporation EW $51.82B 53.5
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Edwards Lifesciences Corporation trades at a P/E of 53.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 DXCM

DexCom, Inc.

$33.17B

 GEHC

GE HealthCare Technologies Inc.

$31.10B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Visit website →